Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema as of March 2024

MARA Rating Company December 16, 2025

Foslevodopa-foscarbidopa for treating advanced levodopa-responsive Parkinson’s with motor symptoms as of November 2023

MARA Rating Company December 16, 2025

Dupixent / dupilumab for treating severe asthma with type 2 inflammation as of December 2021

MARA Rating Company December 16, 2025

Dupixent / dupilumab for treating moderate to severe prurigo nodularis as of March 2024

MARA Rating Company December 16, 2025

Durvalumab / imfinzi for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation as of June 2022

MARA Rating Company December 16, 2025

Durvalumab for treating unresectable or advanced biliary tract cancer as of January 2024

MARA Rating Company December 16, 2025

Durvalumab for treating resectable non-small-cell lung cancer as of January 2025

MARA Rating Company December 16, 2025

Durvalumab for untreated extensive-stage small-cell lung cancer as of February 2025

MARA Rating Company December 16, 2025

Edoxaban / lixiana for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation as of July 2021

MARA Rating Company December 16, 2025

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over as of April 2025

MARA Rating Company December 16, 2025